Skip to main content
Premium Trial:

Request an Annual Quote

First Databank, Translational Software Collaborate on Pharmacogenomics

NEW YORK (GenomeWeb) – First Databank and Translational Software (TSI) today announced a collaboration on incorporating pharmacogenomic data into health information systems.

Under the terms of the agreement, the partners will combine First Databank's MedKnowledge with TSI's pharmacogenomics database and integrate that combo into clinical workflows.

"This functionality will help guide clinical decision making, minimize adverse reactions, and enable physicians to prescribe the most effective medication in a manner that meets the unique needs of individual patients," the firms said in a statement. First Databank President Charles Tuchinda added that the deal expands the firm's clinical care guidance capabilities into pharmacogenomics.

"We now have a treasure trove of pharmacogenomic data," he said.

TSI, based in Mercer Island, Washington, is developing software to generate curated reports to be used in clinical decision support. In November, the firm announced a deal to include its platform into e-prescribing software from DrFirst.

First Databank added that the combined drug knowledge will be deployed on the firm's Cloud Connector platform, providing interoperability with whatever drug knowledge provider underlies a particular electronic health record.

Financial and other terms of the deal were not disclosed.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.